
Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS ’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
In an era defined by uncertainty and increasing organizational complexity, the pressure on health and life science leaders to drive successful launches has reached a critical point. Traditional playbooks for bringing assets to market are being rewritten by technological shifts, shorter clinical-to-launch timelines, and a competitive landscape that moves faster than ever before. To explore what separates high-performing organizations from the rest, Remco op den Kelder, Global President of Inizio Ignite dives into leadership strategies that will define the next three to five years of the industry.
Key Objectives






